NEW YORK (GenomeWeb News) – Agilent Technologies said after the close of the market on Thursday that revenues for its fiscal fourth quarter were down 3 percent year over year, but the company still beat the average analyst estimate on the top and bottom lines.

For the three months ended Oc. 31, Agilent's total revenues dipped to $1.72 billion, compared to $1.77 billion a year ago, edging out the consensus Wall Street estimate of $1.71 billion.

The company had $1.83 billion in orders, up almost 5 percent from $1.75 billion a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

CNBC reports that Amazon invested in the startup Grail as it sees an opportunity for its cloud computing company in genomics.

Lawrence Krauss writes at Slate that science is needed for good public policy and should not be ignored.

Researchers are working on re-making the yeast genome from scratch, according to the Associated Press.

In Cell this week: functional profiling of Plasmodium genome, a self-inactivating rabies virus, and more.